Anjan Chatterji, Mba, J.D., Ll.M.

With the support of the NIHs presigious National Heart, Lung, & Blood Institute, Improving the efficacy and eradicating the adverse health effects of legacy conventional ventilators with our VentSafe multi-frequency technology, specially aimed at reducing ARDS incidence and lowering sedation needs. VentSafe, founded by critical care surgeon Sean Degmetich, who built a team of renowned engineer Dr. Dean Barker and serial healthcare entrepreneur/ICU survivor Anjan Chatterji, plans to disengauge from the traditional ICU model and supersede its static innovation with a fully adaptive model. Info@ventsafemedical.com Gc@ventsafemedical.com SAFE VENTS. SAVE LIVES. #SAFEVENTSSAVELIVES

We are in the business of addressing the problem within the problem. We focus on the details and connections that other, major pharma companies have left ignored for years. There are better ways, better drugs and better formulations and we will make them a reality by analyzing, understanding and solving the problems within the problems.

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company’s FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company’s FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

Star51 Capital is a venture investment vehicle designed to bridge the gap between innovation and acquisition. Anchored by top US academic hospital system and a top-tier global Medtech strategic company, the fund focuses on the convergence of Medtech and AI, leveraging deep industry ties to accelerate market entry and liquidity.

Synergistic plant based cream (no steroids, parabens, sulfates, or harmful alcohols) that targets redness, itch, and eczema, which affects more than 10 percent of the US population.

With the support of the NIHs presigious National Heart, Lung, & Blood Institute, Improving the efficacy and eradicating the adverse health effects of legacy conventional ventilators with our VentSafe multi-frequency technology, specially aimed at reducing ARDS incidence and lowering sedation needs. VentSafe, founded by critical care surgeon Sean Degmetich, who built a team of renowned engineer Dr. Dean Barker and serial healthcare entrepreneur/ICU survivor Anjan Chatterji, plans to disengauge from the traditional ICU model and supersede its static innovation with a fully adaptive model. Info@ventsafemedical.com Gc@ventsafemedical.com SAFE VENTS. SAVE LIVES. #SAFEVENTSSAVELIVES

The natural selection in the evolution of diagnostics. NOMADX is pioneering new technologies for biological and chemical detection that include innovative products that will enable faster, more accurate testing in food, water, and air safety. NOMADX cartridge-enhanced Surface-Enhanced Raman Scattering platform is a patented surface coating that is applied to silicon chips using metallic nanoparticles. The technology significantly enhances the electromagnetic and chemical spectral scattering signal of molecules within a sample to create a multiplex platform. Studies have shown that the platform is as fast and simple to use as an ATP-based test, with results that can exceed the sensitivity, specificity, and speed of traditional PCR testing.

Wilson Chatterji Ventures partners with passionate founders that aim to create a significant social impact in rare and incurable diseases within the biopharmaceutical and med-tech arena. We help founders with their revolutionary ideas across the start-up lifecycle - from concept to commercialization.